Group B (DPCP group)
wart, eczematous reaction
WART
In this group, all the patients were subjected to DPCP solution (manufacture date: Feb. 2018, expiry date: Feb. 2021, Batch No. B22018, origin: Merck KGaA) at a concentration of 0.1% applied to the upper inner arm to induce sensitization using a cotton-tipped applicator. The application site was examined the following week for any eczematous reaction. Once the patient was sensitized, DPCP was applied to the mother wart with concentration starting from 0.1% and gradually increased (up to 2%) until a mild eczematous reaction was noticed. Application was performed weekly until the lesion cleared or completion of a maximum of five treatment sessions. The concentration of DPCP was adjusted according to the severity of the inflammatory reaction from the previous application.